EBITDA: Income before interest, taxes, depreciation and amortization.
COSCIENS Biopharma Inc. (T.CSC) had EBITDA of -3.00M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
-3.74M |
|
-- |
|
-- |
|
-- |
|
-3.25M |
|
-- |
|
-3.73M |
|
-3.73M |
|
-3.74M |
|
-3.74M |
|
-3.74M |
|
-3.74M |
|
-3.25M |
|
|
EBITDA |
-3.00M |
3.17M |
|
3.17M |
|
-1.18 |
|
-1.18 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
38.12M |
|
-- |
|
-- |
|
-- |
|
28.30M |
|
9.82M |
|
9.82M |
|
9.82M |
|
3.17M |
|
| Cash Flow Statement Financials | |
-8.75M |
|
-0.92M |
|
-0.42M |
|
22.68M |
|
12.91M |
|
-9.77M |
|
-0.11M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.98 |
|
-- |
|
-- |
|
0.22 |
|
0.32 |
|
35.43% |
|
-85.59% |
|
-85.59% |
|
-- |
|
-98.22% |
|
-98.25% |
|
-9.66M |
|
-- |
|
-- |
|
-- |
|
0.10 |
|
0.97 |
|
0.99 |
|
91.11 |
|
-38.06% |
|
-38.06% |
|
-9.80% |
|
-29.53% |
|
3.09 |
|
-3.04 |
|
-2.76 |
|